Liquidia's Losses Widen to $79.9M Despite YUTREPIA Sales Boost

Ticker: LQDA · Form: 10-Q · Filed: Aug 12, 2025

Sentiment: bearish

Topics: Biopharmaceutical, Rare Diseases, Pulmonary Arterial Hypertension, Net Loss, YUTREPIA, Debt, Commercialization

Related Tickers: LQDA, UTHR, SNDZ

TL;DR

**LQDA is burning cash at an alarming rate, and while YUTREPIA sales are a start, the ballooning losses and debt make it a risky bet for the short term.**

AI Summary

Liquidia Corp (LQDA) reported a net loss of $79.946 million for the six months ended June 30, 2025, a significant increase from the $58.751 million loss in the same period of 2024. Total revenue for the six months ended June 30, 2025, grew to $11.957 million, up from $6.631 million in 2024, primarily driven by $6.517 million in product sales from YUTREPIA, which had no sales in the prior year. Service revenue, however, decreased to $5.440 million from $6.631 million. Operating expenses surged, with selling, general and administrative costs rising to $68.886 million from $40.192 million, and research and development decreasing to $12.987 million from $19.477 million. The company's cash and cash equivalents decreased slightly to $173.422 million as of June 30, 2025, from $176.479 million at December 31, 2024. Long-term debt, current portion, more than doubled to $44.140 million from $18.016 million, indicating increased financial obligations. The company continues to focus on rare cardiopulmonary diseases like PAH and PH-ILD, leveraging its PRINT technology for YUTREPIA and a promotion agreement with Sandoz for generic treprostinil injection.

Why It Matters

Liquidia's widening net loss to $79.946 million, despite the introduction of YUTREPIA product sales, signals significant operational challenges and increased spending, particularly in selling, general, and administrative areas. For investors, this indicates a longer path to profitability and increased cash burn, raising concerns about future financing needs. Employees might face pressure to deliver on commercialization targets for YUTREPIA and L606. Customers could benefit from new treatment options for rare cardiopulmonary diseases, but the company's financial health could impact long-term product support. In the competitive landscape of rare disease treatments, Liquidia's increased debt and substantial losses could hinder its ability to compete effectively against larger pharmaceutical players like United Therapeutics, especially given ongoing patent litigation.

Risk Assessment

Risk Level: high — The net loss for the six months ended June 30, 2025, increased to $79.946 million from $58.751 million in the prior year, representing a 36% increase in losses. Selling, general and administrative expenses surged by 71% to $68.886 million from $40.192 million, indicating substantial commercialization costs. Furthermore, current long-term debt more than doubled to $44.140 million from $18.016 million, significantly increasing financial obligations and liquidity risk.

Analyst Insight

Investors should exercise extreme caution and consider reducing exposure to LQDA given the accelerating net losses and rising debt. Monitor YUTREPIA's sales trajectory closely and assess if the revenue growth can outpace the escalating operating expenses and interest costs in future quarters.

Financial Highlights

debt To Equity
15.95
revenue
$11.957M
operating Margin
-821.7%
total Assets
$257.410M
total Debt
$193.610M
net Income
-$79.946M
eps
-$0.94
gross Margin
N/A
cash Position
$173.422M
revenue Growth
+80.0%

Revenue Breakdown

SegmentRevenueGrowth
Product Sales (YUTREPIA)$6.517MN/A
Service Revenue$5.440M-18.0%

Key Numbers

Key Players & Entities

FAQ

What were Liquidia Corp's total revenues for the six months ended June 30, 2025?

Liquidia Corp's total revenues for the six months ended June 30, 2025, were $11.957 million, an increase from $6.631 million for the same period in 2024. This growth was primarily driven by $6.517 million in product sales from YUTREPIA.

How did Liquidia Corp's net loss change in the first half of 2025 compared to 2024?

Liquidia Corp's net loss significantly widened to $79.946 million for the six months ended June 30, 2025, compared to a net loss of $58.751 million for the same period in 2024. This represents a 36% increase in net loss.

What is YUTREPIA and how did it contribute to Liquidia Corp's revenue?

YUTREPIA is an inhaled dry powder formulation of treprostinil developed using Liquidia's proprietary PRINT technology. It contributed $6.517 million in product sales, net, to Liquidia Corp's total revenue for the six months ended June 30, 2025, marking its first significant product sales contribution.

What were Liquidia Corp's selling, general and administrative expenses for the six months ended June 30, 2025?

For the six months ended June 30, 2025, Liquidia Corp's selling, general and administrative expenses were $68.886 million. This is a substantial increase from $40.192 million reported for the same period in 2024, reflecting increased commercialization efforts.

What is the current status of Liquidia Corp's litigation with United Therapeutics?

Liquidia Corp is involved in ongoing patent litigation with United Therapeutics in the U.S. District Court for the District of Delaware and the U.S. District Court for the Middle District of North Carolina, as well as litigation in the Superior Court for Durham County, North Carolina. United Therapeutics is seeking remedies that include the removal of YUTREPIA from the market.

How much cash and cash equivalents did Liquidia Corp have as of June 30, 2025?

As of June 30, 2025, Liquidia Corp had $173.422 million in cash and cash equivalents. This is a slight decrease from $176.479 million reported at December 31, 2024.

What is Liquidia Corp's primary business focus?

Liquidia Corp is a biopharmaceutical company primarily focused on the development, manufacture, and commercialization of products addressing unmet patient needs in rare cardiopulmonary diseases, specifically pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

What was the change in Liquidia Corp's current long-term debt?

Liquidia Corp's current long-term debt significantly increased to $44.140 million as of June 30, 2025, from $18.016 million at December 31, 2024. This represents more than a doubling of its short-term debt obligations.

What are the key risks highlighted by Liquidia Corp in its 10-Q filing?

Key risks highlighted include the ability to maintain regulatory approvals for products like YUTREPIA, the outcome of patent litigation with United Therapeutics, the timing and ability to obtain regulatory approvals for product candidates like L606, and the ability to manage increasing operating expenses and debt obligations.

How many shares of common stock were outstanding for Liquidia Corp as of August 4, 2025?

As of August 4, 2025, there were 86,091,454 shares of Liquidia Corp's common stock outstanding.

Risk Factors

Industry Context

The rare cardiopulmonary disease market, particularly for Pulmonary Arterial Hypertension (PAH), is characterized by high unmet needs and significant therapeutic innovation. Companies like Liquidia leverage specialized technologies like PRINT to develop novel drug formulations. However, the market is also competitive, with established players and ongoing research into new treatment modalities, demanding continuous innovation and effective market access strategies.

Regulatory Implications

Liquidia operates in a highly regulated pharmaceutical environment. The success of YUTREPIA and future pipeline products hinges on navigating complex FDA approval processes and post-market compliance. Any shifts in regulatory standards or increased scrutiny on drug pricing and manufacturing could pose significant challenges and impact financial performance.

What Investors Should Do

  1. Monitor YUTREPIA sales trajectory and market penetration closely.
  2. Analyze the sustainability of the current cash burn rate.
  3. Evaluate the impact of increased debt levels on financial flexibility.
  4. Scrutinize R&D spending efficiency and pipeline progress.
  5. Assess the competitive landscape and market access strategies.

Glossary

YUTREPIA
A liquid formulation of treprostinil, a prostacyclin vasodilator used to treat pulmonary arterial hypertension (PAH). (It is Liquidia's primary product driving new revenue, with $6.517 million in sales in H1 2025.)
PRINT technology
Particulate Reinforcement In Non-spherical הטכנולוגיה (PRINT) is a proprietary manufacturing technology used by Liquidia to create precise, uniform particles for drug delivery. (This technology is leveraged for the development and manufacturing of YUTREPIA.)
Pulmonary Arterial Hypertension (PAH)
A rare, progressive condition characterized by high blood pressure in the arteries of the lungs and the right side of the heart. (This is the primary disease indication for Liquidia's lead product, YUTREPIA.)
Accumulated deficit
The cumulative net losses of a company since its inception, minus any cumulative net income. (Liquidia's accumulated deficit was $(637.335) million as of June 30, 2025, reflecting its history of losses.)
Long-term debt, current
The portion of long-term debt that is due within one year. (This figure more than doubled to $44.140 million, indicating increased short-term financial obligations.)
Indemnification asset, related party
An asset recognized when a company has a right to be indemnified by a related party, often in the context of legal settlements or agreements. (The $8.284 million balance suggests potential ongoing legal or contractual arrangements with associated parties.)
Cost of product sales
The direct costs attributable to the production of goods sold by a company. (This is a new expense category for Liquidia, totaling $205 thousand in H1 2025 due to YUTREPIA sales.)
Operating lease right-of-use assets, net
An asset representing the right to use an asset for the lease term under an operating lease. (This reflects Liquidia's obligations for leased assets, with a balance of $4.075 million as of June 30, 2025.)

Year-Over-Year Comparison

Liquidia Corp. has seen a significant increase in total revenue for the first six months of 2025, reaching $11.957 million compared to $6.631 million in the prior year, primarily due to the introduction of YUTREPIA product sales. However, this revenue growth has been overshadowed by a substantial increase in operating expenses, particularly SG&A, which rose 71% to $68.886 million, leading to a wider net loss of $79.946 million. While cash reserves saw a slight decrease, long-term debt, current portion, more than doubled, indicating increased financial obligations and a potentially tighter financial position despite revenue gains.

Filing Stats: 4,434 words · 18 min read · ~15 pages · Grade level 20 · Accepted 2025-08-12 06:45:29

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1. Condensed Financial Statements (unaudited) 6 Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 6 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2025 and 2024 7 Condensed Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended June 30, 2025 and 2024 8 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 9 Notes to Condensed Consolidated Financial Statements 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 36 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 45 Item 4.

Controls and Procedures

Controls and Procedures 45

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 46 Item 1A.

Risk Factors

Risk Factors 46 Item 5. Other Information 94 Item 6. Exhibits 95

Signatures

Signatures 96 This Quarterly Report on Form 10-Q, includes our trademarks, trade names and service marks, such as Liquidia, the Liquidia logo, YUTREPIA and PRINT, which are protected under applicable intellectual property laws and are the property of Liquidia Technologies, Inc. This Quarterly Report on Form 10-Q also contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this Quarterly Report on Form 10-Q may appear without the , or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties' trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. 2 Table of Contents Cautionary Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q may be forward-looking statements. We intend such forward-looking statements to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The forward-looking statements are contained principally in the sections entitled "Risk Factors," and "Management's Discussion and Analysis of Financial Condition and Results of Operations," but are also contained elsewhere in this Quarterly Report on Form 10-Q. In some cases, you can identify forward-looking

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Financial Statements

Item 1. Condensed Financial Statements Liquidia Corporation Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 173,422 $ 176,479 Accounts receivable, net 9,968 2,719 Inventory 6,444 241 Prepaid expenses and other current assets 5,749 5,666 Total current assets 195,583 185,105 Property, plant and equipment, net 9,540 8,298 Operating lease right-of-use assets, net 4,075 4,187 Indemnification asset, related party 8,284 7,460 Contract acquisition costs, net 7,049 7,286 Intangible asset, net 3,052 3,156 Goodwill 3,903 3,903 Restricted cash 3,504 — Other assets 22,420 10,918 Total assets $ 257,410 $ 230,313 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 11,346 $ 4,689 Accrued expenses and other current liabilities 22,522 18,659 Long-term debt, current 44,140 18,016 Operating and finance lease liabilities, current 402 417 Total current liabilities 78,410 41,781 Litigation finance payable 7,970 7,300 Long-term debt, noncurrent 149,470 95,268 Operating and finance lease liabilities, noncurrent 6,371 6,586 Total liabilities 242,221 150,935 Commitments and contingencies (Note 12) Stockholders' equity: Preferred stock — 10,000,000 shares authorized, none outstanding — — Common stock — $ 0.001 par value, 115,000,000 shares authorized as of June 30, 2025 and December 31, 2024, respectively, 85,860,949 and 84,683,063 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 86 85 Additional paid-in capital 652,438 636,682 Accumulated deficit ( 637,335 ) ( 557,389 ) Total stockholders' equity 15,189 79,378 Total liabilities and stockholders' equity $ 257,410 $ 230,313 The accompanying notes are an integral part of these condense

View on Read The Filing